BioSpace News Archive

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced that Jazz has exercised its option to continue with its exclusive development and commercialization rights to Zymeworks’ zanidatamab.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on January 9, 2023, at 8:30 a.m. ET, it will present topline data from the SEQUOIA Phase 2 study evaluating fazirsiran and provide an outline of a Phase 3 study that was co-developed with and will be run by Takeda.

InflaRx will provide access to certain clinical, manufacturing and regulatory documentation for vilobelimab to facilitate STS’s regulatory filings in China STS plans to request regulatory approval in China for its own anti-C5a-antibody BDB-001 for the treatment of COVID-19 based on InflaRx’s technology in-licensed by STS.

Zymeworks Inc. today announced that management will participate in an upcoming investor conference.

Dimension led the round with multiple new institutional investors and significant participation from current investors; Silicon Valley Bank provided the debt facility.

Precision Medicine Asia Co., Ltd. and National Cancer Center Hospital East announced the initiation of the Lung Cancer Genomic Screening Project for Individualized Medicine in Asia Pacific, a genomic screening platform, which will be integrated with LC-SCRUM-Asia to create an international, large scale lung cancer clinicopathological genomic database for the region.

Poolbeg Pharma announces that it has successfully identified potential new drug candidates from its Respiratory Syncytial Virus artificial intelligence Programme with OneThree Biotech, Inc.

ADC Therapeutics SA and Swedish Orphan Biovitrum AB announced the European Commission has granted conditional marketing authorization for the use of ZYNLONTA® for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Ethris GmbH announced a collaboration with UK-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of Betacoronaviruses utilizing the company’s highly differentiated mRNA modification and design technologies as well as its lipidoid nanoparticle and stabilisation platforms.

Acutus Medical, Inc. today announced that the Company has achieved the second milestone under the asset purchase agreement with Medtronic of its left-heart access portfolio with the submission for CE Mark of this portfolio under European Union (EU) Medical Device Regulations (MDR).